Skip to content

Effects of long-term infusion of different dosage forms of propofol on lipid metabolism in patients with hyperlipidemia: a prospective, randomized controlled study

Effects of long-term infusion of different dosage forms of propofol on lipid metabolism in patients with hyperlipidemia: a prospective, randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088910
Enrollment
Unknown
Registered
2024-08-29
Start date
2024-09-10
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemia

Interventions

Experimental group:Anesthesia induction: intravenous injection of fospropofol disodium 10mg/kg, anesthesia maintenance: intravenous infusion of fospropofol disodium 10mg/(kg · h), 30 minutes before th
Control group:Anesthesia induction: intravenous injection of propofol medium/long chain fat emulsion 2mg/kg, anesthesia maintenance: intravenous infusion of propofol medium/long chain fat emulsion 4mg

Sponsors

Guangyuan first people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) ASA grade ? - ?; (2) There is no limit on gender, and the age is between 14 and 65 years old; (3) Estimated operation time > 3 hours; (4) Preoperative serum triglyceride = 1.70mmol/l, cholesterol = 5.20mmol/l.

Exclusion criteria

Exclusion criteria: (1) Patients scheduled for hepatobiliary pancreatic surgery; (2) Preoperative use of drugs that affect blood lipids; (3) Preoperative abnormal liver function (alt>40u/l, ast>40u/l) or use of drugs that damage liver enzymes; (4) Preoperative history of pancreatitis; (5) Have a history of drug abuse or long-term drinking; (6) Serious mental illness; (7) Patients with intraoperative blood loss>20% of total blood volume or massive blood transfusion; (8) Body mass index (BMI)29kg/m2.

Design outcomes

Primary

MeasureTime frame
Triglyceride;Total cholesterol;High-density lipoprotein cholesterol;Low density lipoprotein cholesterol;Apolipoprotein A1;Apolipoprotein B;

Secondary

MeasureTime frame
C-reactive protein;Interleukin-6;

Countries

China

Contacts

Public ContactYANG Chuan

Guangyuan first people's Hospital

gyyc120@163.com+86 138 8123 4780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026